Related Experiment Video

Updated: Mar 16, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K

PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia

B Yousefi1, V Shafiei-Irannejad1, A Azimi2

  • 1Tabriz University of Medical Sciences Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine Tabriz Iran.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|August 23, 2016
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARγ) ligands show promise for treating chronic myeloid leukemia (CML). This review explores their potential role in combination therapies to overcome drug resistance in CML patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Peroxisome proliferator-activated receptor gamma (PPARγ) regulates key cellular pathways implicated in cancer.
  • PPARγ is a potential target for anticancer drug development, particularly in hematologic malignancies.
  • Chronic myeloid leukemia (CML) is driven by the Bcr-Abl tyrosine kinase, with current inhibitors achieving limited efficacy in a subset of patients.

Purpose of the Study:

  • To review the potential therapeutic applications of PPAR ligands in the treatment of Chronic Myeloid Leukemia (CML).
  • To explore the role of PPAR ligands as a strategy to overcome resistance to existing CML therapies.

Main Methods:

  • Literature review of studies investigating PPARγ function and its ligands.
  • Analysis of research on PPAR ligands in hematologic malignancies.
  • Evaluation of potential combination therapy strategies involving PPAR ligands for CML.

Main Results:

  • PPARγ ligands modulate cellular differentiation, proliferation, and apoptosis, suggesting anticancer properties.
  • PPAR ligands are being investigated for various hematologic malignancies.
  • Combination therapy with PPAR ligands may offer a strategy to enhance efficacy and overcome resistance in CML treatment.

Conclusions:

  • PPARγ ligands represent a promising avenue for novel CML therapeutic strategies.
  • Further research into PPAR ligands could lead to improved treatment protocols for CML patients, especially those resistant to imatinib.
  • The review highlights the potential of PPAR ligands in the broader context of hematologic cancer treatment.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.7K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.0K